Cabotegravir/rilpivirine (Cabenuva) vs Etravirine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Cabotegravir/rilpivirine (Cabenuva)
Marketed by GlaxoSmithKline
NCT05917509 · Phase 3 · completed
The 171 participants were assigned to active treatment groups without randomization or blinding, which limits the reliability of comparisons between the regimens. The primary outcomes measured virologic suppression. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: March 2027 · NCT06411223 (registry estimate)
Reported efficacy
Percentage of Participants With Plasma Human Immunodeficiency Virus-ribonucleic Acid (HIV-RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Week 48: HIV-1 RNA >=50 copies/mL (FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 8 weeks vs every 4 weeks: 1.7% vs 1.0%, adjusted difference 0.8% (95% CI -0.6 to 2.2); non-inferior against the 4% margin (CT.gov posted results). (met)
Result source: NCT03299049
Etravirine · Intelence
Marketed by Johnson & Johnson
NCT00254046 · Phase 3 · completed
Participants were randomized and blinded to etravirine or placebo on top of background therapy. A significantly larger share of patients on etravirine achieved viral suppression than on placebo.
Reported efficacy
Evaluation of efficacy, tolerability and safety of TMC125 as part of an antiretroviral therapy containing TMC114/ritonavir and an investigator selected optimized background regimen. (24 weeks): Confirmed viral load <50 copies/mL at week 24: TMC125 (etravirine) 56% (170/304) vs placebo 39% (119/308); difference in response rates 17% (95% CI 9-25), p=0.005 (met)
Result source: NCT00254046
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Cabotegravir/rilpivirine (Cabenuva) | Etravirine |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 94% vs 91%vs CAB 30 mg+ABC/3TCNCT02120352125 other results
| 56% vs 39%a+17 vs placeboNCT00254046 |
| HIV-1 RNA 50 copies/mL or more (week 48) | 0% vs 0%vs DTG + RPVNCT03639311 | —Not posted · NCT00255099 |
| CD4 count, change (week 48) | 270.6 vs 369.9vs CAB 30 mg+ABC/3TCNCT0212035236 other results
| —Not posted · NCT00255099 |
HIV-1 RNA below 50 copies/mL (week 48)
- Cabotegravir/rilpivirine (Cabenuva)
- 94% vs 91%vs CAB 30 mg+ABC/3TCNCT02120352
125 other results
- 95% vs 91% NCT02120352
- 80% vs 71% NCT01641809
- 87% vs 71% NCT01641809
- 80% vs 71% NCT01641809
- 85% vs 74% NCT01641809
- 94% vs 96% NCT01641809
- 75% vs 66% NCT01641809
- 85% vs 87% NCT01641809
- 78% vs 69% NCT01641809
- 89% vs 91% NCT01641809
- 80% vs 69% NCT01641809
- 91% vs 91% NCT01641809
- 82% vs 71% NCT01641809
- 92% vs 94% NCT01641809
- 82% vs 68% NCT01641809
- 92% vs 89% NCT01641809
- 80% vs 71% NCT01641809
- 91% vs 94% NCT01641809
- 73% vs 68% NCT01641809
- 83% vs 89% NCT01641809
- 73% vs 68% NCT01641809
- 83% vs 89% NCT01641809
- 75% vs 68% NCT01641809
- 85% vs 89% NCT01641809
- 75% vs 63% NCT01641809
- 85% vs 83% NCT01641809
- 72% vs 0% NCT01641809
- 73% vs 0% NCT01641809
- 70% vs 0% NCT01641809
- 67% vs 0% NCT01641809
- 63% vs 0% NCT01641809
- 65% vs 0% NCT01641809
- 67% vs 0% NCT01641809
- 65% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 63% vs 0% NCT01641809
- 63% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 60% vs 0% NCT01641809
- 52% vs 0% NCT01641809
- 87% vs 74% NCT01641809
- 96% vs 96% NCT01641809
- 85% vs 66% NCT01641809
- 95% vs 87% NCT01641809
- 85% vs 69% NCT01641809
- 95% vs 91% NCT01641809
- 87% vs 69% NCT01641809
- 96% vs 91% NCT01641809
- 85% vs 71% NCT01641809
- 95% vs 94% NCT01641809
- 85% vs 68% NCT01641809
- 95% vs 89% NCT01641809
- 87% vs 71% NCT01641809
- 96% vs 94% NCT01641809
- 85% vs 68% NCT01641809
- 95% vs 89% NCT01641809
- 85% vs 68% NCT01641809
- 95% vs 89% NCT01641809
- 85% vs 68% NCT01641809
- 95% vs 89% NCT01641809
- 84% vs 63% NCT01641809
- 93% vs 83% NCT01641809
- 80% vs 0% NCT01641809
- 80% vs 0% NCT01641809
- 80% vs 0% NCT01641809
- 77% vs 0% NCT01641809
- 80% vs 0% NCT01641809
- 75% vs 0% NCT01641809
- 75% vs 0% NCT01641809
- 74% vs 0% NCT01641809
- 75% vs 0% NCT01641809
- 77% vs 0% NCT01641809
- 75% vs 0% NCT01641809
- 74% vs 0% NCT01641809
- 75% vs 0% NCT01641809
- 75% vs 0% NCT01641809
- 70% vs 0% NCT01641809
- 74% vs 0% NCT01641809
- 70% vs 0% NCT01641809
- 70% vs 0% NCT01641809
- 87% vs 74% NCT01641809
- 96% vs 96% NCT01641809
- 78% vs 66% NCT01641809
- 90% vs 87% NCT01641809
- 85% vs 69% NCT01641809
- 98% vs 91% NCT01641809
- 83% vs 69% NCT01641809
- 96% vs 91% NCT01641809
- 85% vs 71% NCT01641809
- 98% vs 94% NCT01641809
- 83% vs 68% NCT01641809
- 96% vs 89% NCT01641809
- 80% vs 71% NCT01641809
- 92% vs 94% NCT01641809
- 78% vs 68% NCT01641809
- 90% vs 89% NCT01641809
- 72% vs 68% NCT01641809
- 83% vs 89% NCT01641809
- 72% vs 68% NCT01641809
- 83% vs 89% NCT01641809
- 68% vs 63% NCT01641809
- 79% vs 83% NCT01641809
- 68% vs 0% NCT01641809
- 65% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 58% vs 0% NCT01641809
- 58% vs 0% NCT01641809
- 57% vs 0% NCT01641809
- 58% vs 0% NCT01641809
- 57% vs 0% NCT01641809
- 55% vs 0% NCT01641809
- 55% vs 0% NCT01641809
- 53% vs 0% NCT01641809
- 50% vs 0% NCT01641809
- 52% vs 0% NCT01641809
- 53% vs 0% NCT01641809
- 52% vs 0% NCT01641809
- 50% vs 0% NCT01641809
- 52% vs 0% NCT01641809
- 52% vs 0% NCT01641809
- 98% vs 100% NCT03639311
- Etravirine
- 56% vs 39%a+17 vs placeboNCT00254046
HIV-1 RNA 50 copies/mL or more (week 48)
- Cabotegravir/rilpivirine (Cabenuva)
- 0% vs 0%vs DTG + RPVNCT03639311
- Etravirine
- —Not posted · NCT00255099
CD4 count, change (week 48)
- Cabotegravir/rilpivirine (Cabenuva)
- 270.6 vs 369.9vs CAB 30 mg+ABC/3TCNCT02120352
36 other results
- 263.7 vs 346.1 NCT02120352
- 257.5 vs 369.9 NCT02120352
- 264.4 vs 346.1 NCT02120352
- 267.5 vs 281.7 NCT01641809
- 287 vs 279.4 NCT01641809
- 201.4 vs 257.1 NCT01641809
- 269.4 vs 263.8 NCT01641809
- 241.6 vs 262.5 NCT01641809
- 212.8 vs 221.5 NCT01641809
- 213 vs 185.2 NCT01641809
- 205.2 vs 197.4 NCT01641809
- 188.1 vs 178.2 NCT01641809
- 177.7 vs 166.4 NCT01641809
- 180.9 vs 143.4 NCT01641809
- 286.2 vs 281.7 NCT01641809
- 278.1 vs 279.4 NCT01641809
- 254 vs 257.1 NCT01641809
- 266.1 vs 263.8 NCT01641809
- 259 vs 262.5 NCT01641809
- 212.3 vs 221.5 NCT01641809
- 265 vs 185.2 NCT01641809
- 209.9 vs 197.4 NCT01641809
- 193.3 vs 178.2 NCT01641809
- 194.7 vs 166.4 NCT01641809
- 204 vs 143.4 NCT01641809
- 269.4 vs 281.7 NCT01641809
- 261.5 vs 279.4 NCT01641809
- 232 vs 257.1 NCT01641809
- 217.7 vs 263.8 NCT01641809
- 235.1 vs 262.5 NCT01641809
- 203.6 vs 221.5 NCT01641809
- 192 vs 185.2 NCT01641809
- 191.4 vs 197.4 NCT01641809
- 205 vs 178.2 NCT01641809
- 186.4 vs 166.4 NCT01641809
- 172.5 vs 143.4 NCT01641809
- Etravirine
- —Not posted · NCT00255099
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. Cabotegravir/rilpivirine (Cabenuva): 7 of 7 rows · Etravirine: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Cabotegravir/rilpivirine (Cabenuva) Rows use multiple source trials | Etravirine Rows use multiple source trials |
|---|---|---|
| CD4+ absolute change · cells/uL No placebo or comparator arm | 351 cells/uL @ 192wk30 mga,b,c NCT01641809 · Phase 2 · registry result, not featured evidence · pooled show 2 more doses342.3 cells/uL @ 192wk60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 300.8 cells/uL @ 192wk10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled | 149.5 cells/uL @ 192wkb,c NCT00128830 · Phase 2 · registry result, not featured evidence |
| HIV-1 RNA absolute change · log No placebo or comparator arm | -2.215 log @ 324wk30 mga,b,c,d NCT01641809 · Phase 2 · registry result, not featured evidence · pooled show 2 more doses-2.438 log @ 324wk60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled -2.488 log @ 324wk10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled | -1.53 log @ 48wkb,c,d NCT00665847 · Phase 2 · registry result, not featured evidence |
| HIV-1 RNA Less Than 50 Copies responder rate · % of participants No placebo or comparator arm | 87% (n=430) @ 52wke,b,c,f NCT04399551 · Phase 3 · registry result, not featured evidence | 45.5% (n=22) @ 48wk400/100 mga,e,b,c,f NCT00896051 · Phase 2 · registry result, not featured evidence · combination show 1 more dose50% (n=22) @ 48wk300/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination |
| Dropout rate | 13.6%g NCT04982445 · Phase 4 · registry result, not featured evidence show 45 more results—400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 1.1%400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 8.6%Direct to Injections (D2I) NCT04542070 · Phase 3 · registry result, not featured evidence 13.1%Oral lead-in Phase (OLI) NCT04542070 · Phase 3 · registry result, not featured evidence —Q2M NCT04542070 · Phase 3 · registry result, not featured evidence 6.5% NCT04399551 · Phase 3 · registry result, not featured evidence 11.3% NCT04001803 · Phase 3 · registry result, not featured evidence 1.3%CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination —Step 2: CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination —IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 15.6%Q2M NCT03639311 · Phase 2 · registry result, not featured evidence · combination 11.7%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.8%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence 13.3%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 12.5%30 mg NCT00920426 · Phase 2 · registry result, not featured evidence —5 mg NCT00920426 · Phase 2 · registry result, not featured evidence 15.2%30 mg NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 1 (C1) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 1 (C1) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 2 (C2) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 2 (C2) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 3 (C3) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 3 (C3) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4 (C4) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4 (C4) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4h (C4h) CAB200 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination —Part 1: Cohort 4h (C4h) CAB400 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination —Part 2: Cohort 5 (C5) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 2: Cohort 5 (C5) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —30 mg NCT03149848 · Phase 1 · registry result, not featured evidence —300 mg + 30 mg NCT03149848 · Phase 1 · registry result, not featured evidence · combination | n/a: no completion milestoneg NCT00980538 · Phase 3 · registry result, not featured evidence show 13 more results20.3%400 mg once daily NCT00959894 · Phase 2 · registry result, not featured evidence 36%400/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 40%300/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 24.8% NCT00665847 · Phase 2 · registry result, not featured evidence 20.3% NCT00903682 · Phase 2 · registry result, not featured evidence 34.1% NCT00128830 · Phase 2 · registry result, not featured evidence 5%Cohort I: Treatment Experienced, 2 NCT01504841 · Phase 1/2 · registry result, not featured evidence 16.7%Cohort II: Treatment Experienced, NCT01504841 · Phase 1/2 · registry result, not featured evidence —200 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination —200 mg + 600/100 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination 17.9% NCT00871234 · Phase 1 · registry result, not featured evidence 0% NCT01625169 · Phase na · registry result, not featured evidence · combination — NCT01427504 · Phase na · registry result, not featured evidence · combination |
| Discontinued due to AEs | —g NCT04982445 · Phase 4 · registry result, not featured evidence show 45 more results—400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 1.1%Direct to Injections (D2I) NCT04542070 · Phase 3 · registry result, not featured evidence 5.7%Oral lead-in Phase (OLI) NCT04542070 · Phase 3 · registry result, not featured evidence —Q2M NCT04542070 · Phase 3 · registry result, not featured evidence 3.5% NCT04399551 · Phase 3 · registry result, not featured evidence 4.3% NCT04001803 · Phase 3 · registry result, not featured evidence —CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination —Step 2: CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination —IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 1.1%Q2M NCT03639311 · Phase 2 · registry result, not featured evidence · combination 1.7%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence 4.9%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence 0%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 12.5%30 mg NCT00920426 · Phase 2 · registry result, not featured evidence —5 mg NCT00920426 · Phase 2 · registry result, not featured evidence —30 mg NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 1 (C1) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 1 (C1) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 2 (C2) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 2 (C2) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 3 (C3) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 3 (C3) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4 (C4) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4 (C4) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4h (C4h) CAB200 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination —Part 1: Cohort 4h (C4h) CAB400 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination —Part 2: Cohort 5 (C5) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 2: Cohort 5 (C5) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —30 mg NCT03149848 · Phase 1 · registry result, not featured evidence —300 mg + 30 mg NCT03149848 · Phase 1 · registry result, not featured evidence · combination | 6.7%g NCT00980538 · Phase 3 · registry result, not featured evidence show 13 more results3.8%400 mg once daily NCT00959894 · Phase 2 · registry result, not featured evidence 4%400/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 8%300/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 7.9% NCT00665847 · Phase 2 · registry result, not featured evidence 7.6% NCT00903682 · Phase 2 · registry result, not featured evidence 4.7% NCT00128830 · Phase 2 · registry result, not featured evidence —Cohort I: Treatment Experienced, 2 NCT01504841 · Phase 1/2 · registry result, not featured evidence —Cohort II: Treatment Experienced, NCT01504841 · Phase 1/2 · registry result, not featured evidence —200 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination —200 mg + 600/100 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination 7.1% NCT00871234 · Phase 1 · registry result, not featured evidence — NCT01625169 · Phase na · registry result, not featured evidence · combination — NCT01427504 · Phase na · registry result, not featured evidence · combination |
| Serious AEs | 0%g NCT04982445 · Phase 4 · registry result, not featured evidence show 45 more results0%400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 0%400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 1.1%400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 3.6%Direct to Injections (D2I) NCT04542070 · Phase 3 · registry result, not featured evidence 6.3%Oral lead-in Phase (OLI) NCT04542070 · Phase 3 · registry result, not featured evidence 3.4%Q2M NCT04542070 · Phase 3 · registry result, not featured evidence 4% NCT04399551 · Phase 3 · registry result, not featured evidence 7.8% NCT04001803 · Phase 3 · registry result, not featured evidence —CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination 12.7%Step 2: CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination 27%IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 10%IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 27%IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 26.5%IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 11.1%Q2M NCT03639311 · Phase 2 · registry result, not featured evidence · combination —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 0%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.4%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence 17%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 3.3%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.1%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.8%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 3.3%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.6%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 15.2%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 0%30 mg NCT00920426 · Phase 2 · registry result, not featured evidence 0%5 mg NCT00920426 · Phase 2 · registry result, not featured evidence 0%30 mg NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 1 (C1) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 1 (C1) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 2 (C2) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 2 (C2) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 3 (C3) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 12.5%Part 1: Cohort 3 (C3) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 4 (C4) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 4 (C4) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 4h (C4h) CAB200 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination 0%Part 1: Cohort 4h (C4h) CAB400 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination 0%Part 2: Cohort 5 (C5) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 2: Cohort 5 (C5) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%30 mg NCT03149848 · Phase 1 · registry result, not featured evidence 7.1%300 mg + 30 mg NCT03149848 · Phase 1 · registry result, not featured evidence · combination | 10%g NCT00980538 · Phase 3 · registry result, not featured evidence show 13 more results15.2%400 mg once daily NCT00959894 · Phase 2 · registry result, not featured evidence 8%400/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 16%300/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 5% NCT00665847 · Phase 2 · registry result, not featured evidence 13.9% NCT00903682 · Phase 2 · registry result, not featured evidence 21.8% NCT00128830 · Phase 2 · registry result, not featured evidence 25%Cohort I: Treatment Experienced, 2 NCT01504841 · Phase 1/2 · registry result, not featured evidence 50%Cohort II: Treatment Experienced, NCT01504841 · Phase 1/2 · registry result, not featured evidence 0%200 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination 0%200 mg + 600/100 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination 0% NCT00871234 · Phase 1 · registry result, not featured evidence 0% NCT01625169 · Phase na · registry result, not featured evidence · combination 20% NCT01427504 · Phase na · registry result, not featured evidence · combination |
| Most frequent reported AEs | g injection site discomfort 13.6% injection site pain 13.6% fatigue 2.3% NCT04982445 · Phase 4 · registry result, not featured evidence show 40 more results400 mg + 600 mg Q4W injection site pain 32.3% injection site nodule 9.7% injection site induration 2.2% NCT05896748 · Phase 3 · registry result, not featured evidence · combination 400 mg + 600 mg Q4W injection site pain 74.2% injection site nodule 64.5% injection site erythema 51.6% NCT05896748 · Phase 3 · registry result, not featured evidence · combination 400 mg + 600 mg Q4W injection site pain 30.9% injection site nodule 3.2% injection site pruritus 2.1% NCT05896748 · Phase 3 · registry result, not featured evidence · combination injection site pain 65.2% covid-19 17.9% headache 12.5% NCT04542070 · Phase 3 · registry result, not featured evidence injection site pain 60.6% covid-19 19.4% injection site induration 11.4% NCT04542070 · Phase 3 · registry result, not featured evidence Q2M injection site pain 37.9% covid-19 14.5% arthralgia 0% NCT04542070 · Phase 3 · registry result, not featured evidence injection site pain 80.2% covid-19 18.4% injection site induration 11.2% NCT04399551 · Phase 3 · registry result, not featured evidence injection site pain 55.7% injection site discomfort 26.1% fatigue 20% NCT04001803 · Phase 3 · registry result, not featured evidence creatinine renal clearance decreased 19.7% lipase increased 11.3% chills 7% NCT03739996 · Phase 2 · registry result, not featured evidence · combination IM-Q4W injection site pain 99.1% injection site nodule 49.6% nasopharyngitis 47% NCT02120352 · Phase 2 · registry result, not featured evidence · combination IM-Q4W injection site pain 80% injection site nodule 50% nasopharyngitis 50% NCT02120352 · Phase 2 · registry result, not featured evidence · combination IM-Q8W injection site pain 96.5% nasopharyngitis 47% injection site nodule 40% NCT02120352 · Phase 2 · registry result, not featured evidence · combination IM-Q8W injection site pain 91.2% injection site nodule 35.3% covid-19 26.5% NCT02120352 · Phase 2 · registry result, not featured evidence · combination Q2M injection site pain 74.4% covid-19 33.3% upper respiratory tract infection 17.8% NCT03639311 · Phase 2 · registry result, not featured evidence · combination 30 mg headache 21.7% nausea 18.3% upper respiratory tract infection 13.3% NCT01641809 · Phase 2 · registry result, not featured evidence 30 mg upper respiratory tract infection 26.4% diarrhoea 13.2% rash 11.3% NCT01641809 · Phase 2 · registry result, not featured evidence 30 mg upper respiratory tract infection 31.9% back pain 12.8% oropharyngeal pain 12.8% NCT01641809 · Phase 2 · registry result, not featured evidence 60 mg headache 21.3% diarrhoea 18% nausea 18% NCT01641809 · Phase 2 · registry result, not featured evidence 60 mg upper respiratory tract infection 21.8% nausea 14.5% bronchitis 10.9% NCT01641809 · Phase 2 · registry result, not featured evidence 60 mg upper respiratory tract infection 27.5% anxiety 11.8% sinusitis 11.8% NCT01641809 · Phase 2 · registry result, not featured evidence 10 mg nausea 23.3% headache 21.7% diarrhoea 16.7% NCT01641809 · Phase 2 · registry result, not featured evidence 10 mg upper respiratory tract infection 17.3% depression 9.6% diarrhoea 9.6% NCT01641809 · Phase 2 · registry result, not featured evidence 10 mg diarrhoea 13% nasopharyngitis 10.9% gonorrhoea 8.7% NCT01641809 · Phase 2 · registry result, not featured evidence 30 mg dizziness 37.5% (placebo 0%) dyspepsia 25% (placebo 0%) headache 25% (placebo 0%) NCT00920426 · Phase 2 · registry result, not featured evidence 5 mg abdominal pain 0% (placebo 0%) abnormal dreams 0% (placebo 0%) blood bilirubin increased 0% (placebo 50%) NCT00920426 · Phase 2 · registry result, not featured evidence 30 mg atrioventricular block first degree 7.7% decreased appetite 7.7% headache 7.7% NCT04484337 · Phase 1 · registry result, not featured evidence injection site pain 100% aspartate aminotransferase increased 50% blood creatine phosphokinase increased 50% NCT04484337 · Phase 1 · registry result, not featured evidence injection site pain 100% injection site nodule 55.6% injection site erythema 44.4% NCT04484337 · Phase 1 · registry result, not featured evidence injection site haemorrhage 100% injection site nodule 100% injection site pain 100% NCT04484337 · Phase 1 · registry result, not featured evidence injection site erythema 72.7% injection site pain 72.7% injection site induration 45.5% NCT04484337 · Phase 1 · registry result, not featured evidence injection site induration 100% injection site pain 100% injection site bruising 50% NCT04484337 · Phase 1 · registry result, not featured evidence injection site pain 75% headache 37.5% injection site swelling 37.5% NCT04484337 · Phase 1 · registry result, not featured evidence catheter site bruise 50% injection site erythema 50% injection site induration 50% NCT04484337 · Phase 1 · registry result, not featured evidence injection site erythema 100% injection site pain 94.4% headache 77.8% NCT04484337 · Phase 1 · registry result, not featured evidence injection site erythema 100% injection site pain 100% injection site pruritus 87.5% NCT04484337 · Phase 1 · registry result, not featured evidence · combination injection site erythema 100% injection site pain 100% injection site warmth 88.9% NCT04484337 · Phase 1 · registry result, not featured evidence · combination accident 100% injection site nodule 100% injection site pain 100% NCT04484337 · Phase 1 · registry result, not featured evidence injection site pain 100% injection site swelling 70% headache 60% NCT04484337 · Phase 1 · registry result, not featured evidence 30 mg blood creatine phosphokinase increased 6.7% contusion 6.7% body temperature increased 0% NCT03149848 · Phase 1 · registry result, not featured evidence 300 mg + 30 mg body temperature increased 7.1% headache 7.1% hyperkeratosis 7.1% NCT03149848 · Phase 1 · registry result, not featured evidence · combination | g cough 2.8% upper respiratory tract infection 2.8% pregnancy 2.2% NCT00980538 · Phase 3 · registry result, not featured evidence show 13 more results400 mg once daily elevated level of transaminase 11.4% hyperbilirubinemia 7.6% hyperlipidemia 7.6% NCT00959894 · Phase 2 · registry result, not featured evidence 400/100 mg cough 16% headache 12% influenza 12% NCT00896051 · Phase 2 · registry result, not featured evidence · combination 300/100 mg cough 20% nausea 16% blood bilirubin increased 12% NCT00896051 · Phase 2 · registry result, not featured evidence · combination upper respiratory tract infection 26.7% diarrhoea 15.8% cough 12.9% NCT00665847 · Phase 2 · registry result, not featured evidence nasopharyngitis 21.5% headache 16.5% diarrhoea 10.1% NCT00903682 · Phase 2 · registry result, not featured evidence diarrhoea 17.5% upper respiratory tract infection 17.1% sinusitis 11.4% NCT00128830 · Phase 2 · registry result, not featured evidence blood bicarbonate decreased 90% blood sodium decreased 70% nasal congestion 70% NCT01504841 · Phase 1/2 · registry result, not featured evidence cough 100% nasal congestion 100% rhinorrhoea 100% NCT01504841 · Phase 1/2 · registry result, not featured evidence 200 mg + 200 mg headache 18.8% toothache 12.5% diarrhoea 6.3% NCT04630002 · Phase 1 · registry result, not featured evidence · combination 200 mg + 600/100 mg + 200 mg rash maculo-papular 20% scleral hyperaemia 20% headache 13.3% NCT04630002 · Phase 1 · registry result, not featured evidence · combination headache 14.3% constipation 10.7% diarrhea 7.1% NCT00871234 · Phase 1 · registry result, not featured evidence breast tenderness 66.7% diarrhea 11.1% headache 11.1% NCT01625169 · Phase na · registry result, not featured evidence · combination altered taste 64% headache 16% rash 16% NCT01427504 · Phase na · registry result, not featured evidence · combination |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 324 weeks versus 48 weeks.
- eTrial phases differ: Phase 3 versus Phase 2.
- fAssessment timepoints differ: 52 weeks versus 48 weeks.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Cabotegravir/rilpivirine (Cabenuva)
show 2 more results
show 2 more results
show 1 more result
show 6 more results
show 25 more results
show 1 more result
show 1 more result
show 1 more result
show 6 more results
show 1 more result
+ 168 further endpoints in the CSV export.
Etravirine
show 2 more results
show 2 more results
show 7 more results
show 1 more result
show 7 more results
show 1 more result
show 1 more result
show 1 more result
show 2 more results
show 2 more results
show 1 more result
+ 6 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cabotegravir/rilpivirine (Cabenuva)'s landscape · Etravirine's landscape